This webcast features: Marissa Dickson, Scientist II, & Brian Hadley, Principal Scientist, Lonza Biologics.

One strategy for lowering cost of goods (CoGs) of biotherapeutics manufacturing is by dramatically increasing the productivity of the bioreactor process. Lonza R&D has developed an intensified process that couples a perfused N-1 inoculum bioreactor, enabled by alternating tangential flow filtration, to a fully-automated high inoculation density (HID) production stage reactor. This reactor demonstrates substantial increases in bioreactor productivity compared to a low inoculation density control fed-batch process.

Significant titer increases between LID and HID processes have been demonstrated with a panel of six CHOK1SV GS-KO® cell lines expressing three different monoclonal antibodies. In addition, increases in product concentration while maintaining comparable product quality were observed in process intensification for two cell lines expressing unique novel molecular formats: a monospecific antibody with an Fc-fusion protein and a bispecific antibody.

Key Takeaways:

Register or Login and hit Watch on Demand to view the recorded webcast now.